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TO THE EDITOR
We have recently completed a study that suggests affinity state measurements may be a useful tool in studies of acute leukemia pathogenesis. Cellular adhesion molecules such as VLA-4 (very late antigen-4; CD49d/CD29) play an important role in the survival of normal and leukemic B cells.
1,2 mAb to VLA-4 inhibits lymphopoiesis, 1 and the binding of VLA-4 on precursor B-ALL cells to its ligand vascular cell adhesion molecule-1 (VCAM-1) on BM stromal cells is required for leukemic cell survival. 2, 3 Defective VLA-4-dependent adhesion has also been identified in a subset of precursor B-ALL cases. 3 Yet, the clinical and biologic significance, if any, to defective VLA-4-mediated adhesion on precursor B-ALL cells is unknown.
VLA-4-mediated adhesion is regulated through affinity changes of VLA-4 for VCAM-1. VLA-4 has several affinity states that are due to conformational changes. We have recently developed a means of detecting these affinity changes, which correspond to the affinity for its natural ligands VCAM-1 and fibronectin, using an FITC-labeled VLA-4-specific peptidomimetic. 4 This technology rests on the observation that when these small molecules are used at a concentration that approximates its affinity constant for the high-affinity state, it will bind to the high-affinity state but not the lower affinity state. The rapid on and off rates of peptidomimetics in contrast to mAbs allow them to be used to detect changes in affinity state in real time. 4 MnCl 2 and TS2/16 are two agents that activate VLA-4 to higher affinity states. TS2/16 binds to VLA-4, inducing a higher affinity state, not dependent on cellular signaling.
In this study, we took advantage of this novel technology to examine how alterations in affinity regulation may affect the clinical or biologic features of precursor B-ALL cases. We first assessed VLA-4 affinity changes on a group of 36 diagnostic samples from patients with precursor B-ALL. These samples were obtained from children diagnosed with precursor B-ALL, and selected from precursor B Phase III trials (COG 9400). The cases consisted of 18 males, four of eight standard risk who achieved CCR and five of ten poor risk who achieved CCR; and 18 females, four of seven standard risk and six of 11 poor risk who achieved CCR. The assays were conducted in a blinded fashion, and the results forwarded to the central data center for statistical analysis. The methods used to quantify monoclonal antibody binding and receptor number peptidomimetic binding have been previously described. 4 After all the results were obtained, we received clinical, laboratory, and immunophenotypic data for each patient from the POG tumor bank. We correlated these data using Kruskal-Wallis and Spearman correlation coefficients to determine r and P values, respectively.
Significant differences in VLA-4 expression between CCR and relapse cases were not observed ( Table 1 ). All patient samples expressed VLA-4; however, a striking range of VLA-4 sites/cell was observed (3015-25 526 sites/cell) with a mean of 7402 sites/cell. In contrast, we have previously shown that normal peripheral blood B cells have approximately 4000 sites/cell with a narrow variation among donors. 4 Site number did not change with Mn or TS2/16 treatment (data not shown). In each patient sample, we next examined the VLA-4 affinity state obtained at rest and after stimulation with MnCl 2 and TS2/16. Fluorescence intensity (MESF) is a measure of the affinity state of VLA-4. A statistically significant association between VLA-4 expression and VLA-4 affinity state measurements was not observed among cases (P ¼ 0.09). There were no significant differences among the CCR and relapse groups in terms of their expression or affinity state after stimulation ( Table 2) .
Notably, two cases did not show a significant increase (45% change) in VLA-4 affinity when treated with MnCl 2 or TS2/16 in spite of expressing high numbers of VLA-4 receptors. Both these cases were from the relapse group. We have previously shown that upwards of 100% of VLA-4 receptors change affinity state on normal leukocytes after MnCl 2 or TS2/16 stimulation. 4 These two cases, thus, had VLA-4 expressed on the cell surface, but VLA-4 could not be converted to a higher affinity state (nonactive VLA-4 cases).
In the remaining 34 cases, VLA-4 was converted to a higher affinity state after TS2/16 or MnCl 2 treatment. MnCl 2 stimulation was proportionately greater in comparison to TS2/16 treatment, consistent with the previous observations 4 (data not shown). We then compared the clinical, laboratory, and immunophenotypic findings between the two nonactive VLA-4 cases vs the 34 other cases. The nonactive cases had a higher mean number of VLA-4 sites/cell, 24 580 (23 634 and 25 526 sites/cell for each case), compared to 8053 (range 3015-19 707) in the other 34 cases. The mean white blood cell count was higher, 322 000 cells/ml, in the nonactive group versus 55 750 cells/ml in the remaining cases. P-values were not calculated since the sample size of the nonactive cases was only two. There was no difference in the hemoglobin and platelet counts between the two cases in the nonactive group and the other 34 cases.
Finally, we correlated VLA-4 affinity changes of the 34 cases with laboratory, clinical, and immunophenotypic data, looking for statistical significance (Table 3) . WBC count had a median value of 70.6, and a statistically significant inverse correlation (Po0.01) was found between WBC count and VLA-4 affinity after stimulation. DNA ploidy was also found to have a statistically significant correlation (Po0.03), with VLA-4 affinity after stimulation. None of the other laboratory (hemoglobin, platelet count), clinical (age, race, sex, presence of liver or spleen involvement, adenopathy), or immunophenotypic (CD10, CD19, CD24, CD22, CD20, CD34) data were found to have a statistically significant correlation with VLA-4 activity level.
These data suggest that decreased VLA-4 activity results in increased circulating lymphoblasts. An increase in circulating cells as a result of VLA-4 inhibition or decreased expression has been shown in other experimental systems. [5] [6] [7] For instance, administration of anti-VCAM-1 antibody induces mobilization of hematopoietic progenitor cells from marrow into blood. 5 Furthermore, increased adhesion occurs during IL-2 therapy, via a VLA-4/VCAM-1 interaction, resulting in a decrease of circulating progenitor cells. 6 Lichterfeld et al 7 found a significantly reduced VLA-4 receptor avidity on CD34-positive cells from peripheral blood cells vs steady-state BM cells, using fluorescence analysis of VCAM-Ig binding, and the amount of circulating CD34+ during marrow recovery was inversely related to the activation state of VLA-4. 7 These findings suggest that modulation of VLA-4 receptor function is involved in mobilization of normal stem cells. Our study suggests that with decreased regulation of VLA-4, that is, when higher affinity states were not obtained, more blasts can enter the circulation, resulting in a higher peripheral WBC count.
We also found a correlation between high DNA content and VLA-4 activity. Hyperdiploidy is known to be a good prognostic factor, in childhood ALL. However, the mechanism is still not definitively understood. Our data suggest that these cases may have greater intrinsic ability to bind the BM stromal cells, in keeping with the lower peripheral WBC counts.
It is perhaps surprising that a correlation between VLA-4 activity and patient outcome was not seen, since it is well known that WBC count and patient outcome are correlated. This apparent discordance is likely explained by the weak correlation between WBC and patient outcome. Since these two variables are weakly correlated, a correlation between VLA-4, WBC, and patient outcome will not necessarily be observed. In all, these findings emphasize that the evaluation No statistically significant differences are noted among groups in terms of resting or stimulated affinity of VLA-4. TO THE EDITOR It is generally accepted that EVI1, inappropriately expressed in hematopoietic cells after rearrangements of the 3q26 chromosomal band, is also aberrantly expressed in leukemic samples without 3q26 abnormality, which is the site of the EVI1 locus.
1,2
EVI1 was initially described in murine myeloid leukemia, where it was shown to be activated by proviral insertion in the Evi-1 common integration site. 3 More recently, EVI1 was shown to be part of a fusion gene named MDS1-EVI1, which results from the in-frame splicing of EVI1 and MDS1, a gene mapped 150-300 kb upstream of EVI1. 4 Based on Fears et al data, 4 the sequence of EVI1 after the MDS1-EVI1 splice junction starts with the second exon of EVI1 as reported by Morishita et al 5 and continues to the end of Morishita's EVI1 cDNA. Hence, EVI1 and MDS1-EVI1 transcripts share a strong homology in nucleotide sequences, the two transcripts differing only at their extreme 5 0 ends where they have unique sequences. 4 The amplified products that have been detected, using common primers, by several authors 1,2 in leukemic samples without 3q26 rearrangement could therefore belong to MDS1-EVI1 rather than EVI1. To shed some light on this issue, we designed primers specific for the 5 0 end of both genes. Taking advantage of an RNA collection, we performed a discriminating screening between MDS1-EVI1 and EVI1 by RT-PCR in 34 samples obtained from patients with myeloid neoplasms (Table 1) referred to our laboratory for routine cytogenetic and molecular diagnoses (BCR-ABL transcript detection). Previous analyses had proved all 34 specimens to be positive by RT-PCR, using primers described in the literature, 5 for the common distal 3 0 end of MDS1-EVI1 and EVI1, and negative for 3q26 chromosomal band rearrangements by routine conventional and molecular cytogenetics (whole-chromosome painting with a probe specific for chromosome 3). We report that MDS1-EVI1 was expressed in all 34 analyzed cases. In contrast, EVI1 was expressed in only seven patients, concomitantly to the MDS1-EVI1 transcript.
Total RNA was prepared by lysis of bone marrow or peripheral blood mononuclear cells, and nucleic acid extraction was carried out with Trizol reagent. cDNA synthesis was performed using random hexamer primers (Boehringer Mannheim, Meylan, France) with 2.5 mg of total RNA in a total volume of 50 ml following standard procedures. 6 The cDNA samples were then subjected to PCR analysis for the various products using a thermal cycler 480 Applied Biosystems. The amplification reaction mixture contained 1.25 U Taq/50 ml (ampliTaq, Applied Biosystems, 78 St Quentin, France), 250 mM dNTPs (Boehringer Mannheim, Meylan, France), and 1 Â PCR buffer. Sequences, positions of the oligonucleotide primers and probes, as well as cycle conditions used in this study are shown in Figure 1a and Table 2 . To confirm the integrity of the isolated RNA and the correctness of cDNA synthesis, the ubiquitously expressed c-ABL gene was amplified in a separate PCR reaction. Each PCR assay included RNA extracted from K562 cells and HL60 cells as positive and negative controls, respectively. Leukemic cells bearing 3q26 rearrangements, either inv(3)(q21q26) or t(3;21), were also used to confirm the specificity of our set of primers. In addition, RT-PCR reactions without reverse transcriptase or with water rather than input RNA were carried out for each sample as controls of reagent contamination. After amplification, the PCR products were size fractionated by electrophoresis in 2% Nusieve/agarose gel and visualized by ethidium bromide staining. The specificity of the amplification products was confirmed by Southern blot analysis of the amplified fragments after transfer to a nylon membrane and hybridization to specific internal nonisotopic labelled oligoprobes.
The results of the discriminating screening by RT-PCR analyses are summarized in Table 1 . Amplification of the 5 0 end of EVI1, using primers specific for the 5 0 unique nontranslated first exon and for the second translated exon of EVI1 (exon 4), failed to produce, in the majority (27/34) of our cases, the 562 bp product that would be expected based on the sequence data. 5 Contrasting with data reported in the literature, this result would indicate that a full-length EVI1 transcript is
